The Pharma Letter Podcast — Episode 27 — How to develop cancer drugs faster, with Ellipses Pharma

Simon Wentworth

23 January 2024

episode-27-big

More on this story...

The trust complex - strengthening the fundamentals of communications is more important than ever

8 February 2024

Growing J&J sales tempered by rising costs

23 January 2024

Positive pharma report finds increased funding, productivity and product launches in 2023

26 February 2024

BRIEF—Trends shaping healthcare marketplace analyzed in report

2 February 2024

Related Company News

Ellipses’ selective RET inhibitor granted Fast Track designation by FDA

The need to transform the clinical trial landscape

What's to come at ASH 2022: selected highlights

Ellipses pays for global rights to SunRock compound

More ones to watch >

More Features in Biotechnology

Forbion expands to Boston, hires former Dyne CEO

1 July 2024

Another win for nipocalimab as J&J closes in on rivals

1 July 2024

New Ajovy data challenges treatment breaks in migraine prevention

1 July 2024

Zenas BioPharma appoints Orlando Oliveira as CCO

1 July 2024

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze